Jeffrey D. Abbey
Directeur des opérations chez ImmunOs Therapeutics AG
Profil
Jeffrey D.
Abbey is currently the Director at NC Life Sciences Organization and Director at DC Bio Corp.
He is also the Chief Operating Officer at ImmunOs Therapeutics AG since 2021.
Previously, he was the Chief Executive Officer & Director at Novadip Biosciences SA. He was also the Vice President-Finance & Business Development at Internet Appliance Network from 1999 to 2001.
Additionally, he was the Chief Business Officer at Argos Therapeutics, Inc. from 2009 to 2010.
Prior to that, he was a Partner at Eilenberg & Krause LLP from 1994 to 1999.
Mr. Abbey completed his undergraduate degree at Brown University and his graduate degree, including an MBA, at the University of Virginia.
Postes actifs de Jeffrey D. Abbey
| Sociétés | Poste | Début |
|---|---|---|
NC Life Sciences Organization
 NC Life Sciences Organization Miscellaneous Commercial ServicesCommercial Services North Carolina Biosciences Organization is non-profit organization, which focuses on legislative monitoring and lobbying activities at the state and federal level. The company was founded in 1994 and is headquartered in Durham, NC. | Directeur/Membre du Conseil | - |
DC Bio Corp.
 DC Bio Corp. BiotechnologyHealth Technology DC Bio Corp. develops technology for application to cancer and diseases associated with chronic viral infections. The company is headquartered in Halifax, Canada. | Directeur/Membre du Conseil | - |
ImmunOs Therapeutics AG
 ImmunOs Therapeutics AG BiotechnologyHealth Technology ImmunOs Therapeutics AG is a company based in Schlieren, Switzerland that pioneers HLA-based therapeutics to create transformational medicines for cancer and inflammation. The Swiss company has identified specific HLA molecules that activate the immune system and is utilizing these molecules as the backbone of novel therapies capable of stimulating both the innate and adaptive immune systems of cancer patients to eliminate tumor cells. ImmunOs' lead program is a multi-functional fusion protein that blocks specific LILRB and KIR receptors and activates anti-tumor responses. The company is also using HLA molecules to develop novel therapies to treat inflammatory diseases. ImmunOs is supported by leading international investors, including Samsara BioCapital, Lightspeed Venture Partners, Gimv, Pfizer Ventures, Biomed Partners, Schroder Adveq, Mission BioCapital, GL Capital, Peak6, Fiscus, and Redalpine. The company was founded by Osiris Marroquin Belaunzaran and Christoph Renner, and the CEO is Sean R. Smith. | Directeur des opérations | 01/09/2021 |
Anciens postes connus de Jeffrey D. Abbey
| Sociétés | Poste | Fin |
|---|---|---|
| Internet Appliance Network | Directeur Financier/CFO | 01/01/2001 |
Eilenberg & Krause LLP
 Eilenberg & Krause LLP Miscellaneous Commercial ServicesCommercial Services Eilenberg & Krause LLP provides legal services. The private company is based in New York, NY. | Corporate Officer/Principal | - |
Novadip Biosciences SA
 Novadip Biosciences SA BiotechnologyHealth Technology Novadip Biosciences SA operates as a advanced biopharmaceutical company that develops cell-based therapies to treat patients with critical size bone defects and severe bone diseases. Its proprietary product, Creost, is a natural scaffold-free and tridimensional bone structure, which reconstructs large bone defects without the need of any biomaterial. The firm is a osteogenic living implant with a mineralization similar to a real bone. Its Creost is an autologous cell based-therapy product obtained from Adipose-derived Mesenchymal Stem Cells (AMSCs) which promotes (i) a perfect engraftment without any scaffold and (ii) a tissue remodeling with all native bone properties. Novadip Biosciences was founded by Jean-Fran?ois Pollet and Denis Dufrane in 2013 and is headquartered in Louvain-la-Neuve, Belgium. | Directeur Général | - |
| ARGOS THERAPEUTICS, INC. | Directeur Général | - |
Formation de Jeffrey D. Abbey
| Brown University | Undergraduate Degree |
| University of Virginia | Graduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 7 |
|---|---|
Eilenberg & Krause LLP
Eilenberg & Krause LLP Miscellaneous Commercial ServicesCommercial Services Eilenberg & Krause LLP provides legal services. The private company is based in New York, NY. | Commercial Services |
Argos Therapeutics, Inc.
 Argos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Argos Therapeutics, Inc. was a biopharmaceutical company. It engages in development and commercialization of individualized immunotherapies for the treatment of cancer and infectious diseases based on its proprietary technology platform called Arcelis. The firm's product include AGS-003 for the treatment of metastatic renal cell carcinoma, and other cancers; and AGS-004 for the treatment of human immunodeficiency virus. The company was founded by Bruce A. Sullenger, Eli Gilboa, John A. Irick and Ralph M. Steinman on May 8, 1997 and was headquartered in Durham, NC. | Health Technology |
| Internet Appliance Network | Communications |
NC Life Sciences Organization
NC Life Sciences Organization Miscellaneous Commercial ServicesCommercial Services North Carolina Biosciences Organization is non-profit organization, which focuses on legislative monitoring and lobbying activities at the state and federal level. The company was founded in 1994 and is headquartered in Durham, NC. | Commercial Services |
Novadip Biosciences SA
Novadip Biosciences SA BiotechnologyHealth Technology Novadip Biosciences SA operates as a advanced biopharmaceutical company that develops cell-based therapies to treat patients with critical size bone defects and severe bone diseases. Its proprietary product, Creost, is a natural scaffold-free and tridimensional bone structure, which reconstructs large bone defects without the need of any biomaterial. The firm is a osteogenic living implant with a mineralization similar to a real bone. Its Creost is an autologous cell based-therapy product obtained from Adipose-derived Mesenchymal Stem Cells (AMSCs) which promotes (i) a perfect engraftment without any scaffold and (ii) a tissue remodeling with all native bone properties. Novadip Biosciences was founded by Jean-Fran?ois Pollet and Denis Dufrane in 2013 and is headquartered in Louvain-la-Neuve, Belgium. | Health Technology |
DC Bio Corp.
DC Bio Corp. BiotechnologyHealth Technology DC Bio Corp. develops technology for application to cancer and diseases associated with chronic viral infections. The company is headquartered in Halifax, Canada. | Health Technology |
ImmunOs Therapeutics AG
ImmunOs Therapeutics AG BiotechnologyHealth Technology ImmunOs Therapeutics AG is a company based in Schlieren, Switzerland that pioneers HLA-based therapeutics to create transformational medicines for cancer and inflammation. The Swiss company has identified specific HLA molecules that activate the immune system and is utilizing these molecules as the backbone of novel therapies capable of stimulating both the innate and adaptive immune systems of cancer patients to eliminate tumor cells. ImmunOs' lead program is a multi-functional fusion protein that blocks specific LILRB and KIR receptors and activates anti-tumor responses. The company is also using HLA molecules to develop novel therapies to treat inflammatory diseases. ImmunOs is supported by leading international investors, including Samsara BioCapital, Lightspeed Venture Partners, Gimv, Pfizer Ventures, Biomed Partners, Schroder Adveq, Mission BioCapital, GL Capital, Peak6, Fiscus, and Redalpine. The company was founded by Osiris Marroquin Belaunzaran and Christoph Renner, and the CEO is Sean R. Smith. | Health Technology |
